Brief: Context Therapeutics Received Letter From Nasdaq On June 15, Notifying That Co Has Regained Compliance With Minimum Bid Price Rule
20/06/2023 16:14
June 20 (Reuters) - Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS - ON JUNE 15 RECEIVED LETTER FROM
NASDAQ
NOTIFYING THAT CO HAS REGAINED COMPLIANCE WITH MINIMUM BID PRICE
RULE
Further company coverage: CNTX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202